Research Papers

25 of 347 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Who prescribes quetiapine in Denmark?
Højlund M; Rasmussen L; Olesen M; Munk-Olsen T; Pottegård A.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis.
Court R; Gausi K; Mkhize B; Wiesner L; Waitt C; McIlleron H; Maartens G; Denti P; Loveday M.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Human pharmacokinetics of XBD173 and etifoxine distinguish their potential for pharmacodynamic effects mediated by tran…
Owen DR; Phillips A; O'Connor D; Grey G; Aimola L; Nicholas R; Matthews PM.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
A systematic review on disease-drug-drug interactions with immunomodulating drugs: A critical appraisal of risk assessm…
de Jong LM; Klomp SD; Treijtel N; Rissmann R; Swen JJ; Manson ML.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient ch…
Slattery J; Quinten C; Candore G; Pinheiro L; Flynn R; Kurz X; Nordeng H.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Data
Angiotensin-converting enzyme inhibitors and risk of age-related macular degeneration in individuals with hypertension.
Subramanian A; Han D; Braithwaite T; Thayakaran R; Zemedikun DT; Gokhale KM; Lee WH; Coker J; Keane PA; Denniston AK; Nirantharakumar K; Azoulay L; Adderley NJ.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and…
Klein S; Gashaw I; Baumann S; Chang X; Hummel T; Thuß U; Friedrich C.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Fatalities associated with gabapentinoids in England (2004-2020).
Kalk NJ; Chiu CT; Sadoughi R; Baho H; Williams BD; Taylor D; Copeland CS.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activ…
Kvitne KE; Krogstad V; Wegler C; Johnson LK; Kringen MK; Hovd MH; Hertel JK; Heijer M; Sandbu R; Skovlund E; Artursson P; Karlsson C; Andersson S; Andersson TB; Hjelmesaeth J; Åsberg A; Jansson-Löfmark R; Christensen H; Robertsen I.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide coh…
Højen AA; Nielsen PB; Riahi S; Jensen M; Lip GYH; Larsen TB; Søgaard M.
Br J Clin Pharmacol (Unknown)
Published: 2022
2/6 Transparent
Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled tri…
Asiimwe IG; Pushpakom SP; Turner RM; Kolamunnage-Dona R; Jorgensen AL; Pirmohamed M.
Br J Clin Pharmacol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Changes in suspected adverse drug reaction reporting via the yellow card scheme in Wales following the introduction of …
Deslandes PN; Bracchi R; Jones K; Haines KE; Carey E; Adams A; Walker J; Thomas A; Routledge PA.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulatio…
Roussin A; Soeiro T; Fouque C; Jouanjus E; Frauger E; Fouilhé N; Mallaret M; Micallef J; Lapeyre-Mestre M; French Addictovigilance Network (FAN).
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam.
Kletzl H; Ajmi H; Antys I; Heinig K; Jaber B; Marbury TC; Young A; Günther A.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Risk of out-of-hospital cardiac arrest in patients with epilepsy and users of antiepileptic drugs.
Eroglu TE; Folke F; Tan HL; Torp-Pedersen C; Gislason GH.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis.
Mauer J; Bullok K; Watt S; Whalen E; Russo L; Junor R; Markman J; Hauber B; Tervonen T.
Br J Clin Pharmacol (Unknown)
Published: 2022
2/6 Transparent
Funding Declared
Dose banding - Weighing up benefits, risks and therapeutic failure.
Duffull S.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Comparative effects of low-carbohydrate, full-strength and low-alcohol beer on gastric emptying, alcohol absorption, gl…
Stevens JE; Jalleh RJ; Trahair LG; Marathe CS; Horowitz M; Jones KL.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Characterisation of individual ferritin response in patients receiving chelation therapy.
Borella E; Oosterholt S; Magni P; Della Pasqua O.
Br J Clin Pharmacol (Unknown)
Published: 2022
2/6 Transparent
An e-Delphi study to obtain expert consensus on the level of risk associated with preventable e-prescribing events.
Heed J; Klein S; Slee A; Watson N; Husband A; Slight SP.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme.
O' Donovan B; Rodgers RM; Cox AR; Krska J.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in th…
Sanghavi R; Pana TA; Mamayusupova H; Maidment I; Fox C; Boekholdt SM; Mamas MA; Wareham NJ; Khaw KT; Myint PK.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
A systematic literature review and meta-analysis of community pharmacist-led interventions to optimise the use of antib…
Lambert M; Smit CCH; De Vos S; Benko R; Llor C; Paget WJ; Briant K; Pont L; Van Dijk L; Taxis K.
Br J Clin Pharmacol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response.
Gross AS; Harry AC; Clifton CS; Della Pasqua O.
Br J Clin Pharmacol (Unknown)
Published: 2022
2/6 Transparent
Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with…
Meng A; Anderson K; Nelson C; Ni L; Chuang SM; Bellanti F; Chang P; Comisar C; Kearney BP; Bartok B; Mathias A.
Br J Clin Pharmacol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared